DrugPatentWatch Database Preview

Lonafarnib - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for lonafarnib and what is the scope of freedom to operate?

Lonafarnib is the generic ingredient in one branded drug marketed by Eiger Biopharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lonafarnib has nine patent family members in six countries.

Summary for lonafarnib

International Patents:	9
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	61
Clinical Trials:	31
Patent Applications:	6,546
What excipients (inactive ingredients) are in lonafarnib?	lonafarnib excipients list
DailyMed Link:	lonafarnib at DailyMed

Recent Clinical Trials for lonafarnib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eiger BioPharmaceuticals	Phase 3
Boston Children’s Hospital	Phase 1/Phase 2
Hannover Medical School	Phase 2

See all lonafarnib clinical trials

US Patents and Regulatory Information for lonafarnib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eiger Biopharms	ZOKINVY	lonafarnib	CAPSULE;ORAL	213969-001	Nov 20, 2020		RX	Yes	No
Eiger Biopharms	ZOKINVY	lonafarnib	CAPSULE;ORAL	213969-002	Nov 20, 2020		RX	Yes	Yes
Eiger Biopharms	ZOKINVY	lonafarnib	CAPSULE;ORAL	213969-002	Nov 20, 2020		RX	Yes	Yes
Eiger Biopharms	ZOKINVY	lonafarnib	CAPSULE;ORAL	213969-001	Nov 20, 2020		RX	Yes	No

International Patents for lonafarnib

Country	Patent Number	Estimated Expiration
Japan	2006507845
Japan	4436800
World Intellectual Property Organization (WIPO)	2006081444
Australia	2003301446